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Abstract
Migraine and major depressive disorder (MDD) are comorbid, moderately heritable and to some
extent influenced by the same genes. In a previous paper, we suggested the possibility of causality
(one trait causing the other) underlying this comorbidity. We present a new application of
polygenic (genetic risk) score analysis to investigate the mechanisms underlying the genetic
overlap of migraine and MDD. Genetic risk scores were constructed based on data from two
discovery samples in which genome-wide association analyses (GWA) were performed for
migraine and MDD, respectively. The Australian Twin Migraine GWA study (N = 6350) included
2825 migraine cases and 3525 controls, 805 of whom met the diagnostic criteria for MDD. The
RADIANT GWA study (N = 3230) included 1636 MDD cases and 1594 controls. Genetic risk
scores for migraine and for MDD were used to predict pure and comorbid forms of migraine and
MDD in an independent Dutch target sample (NTR-NESDA, N = 2966), which included 1476
MDD cases and 1058 migraine cases (723 of these individuals had both disorders concurrently).
The observed patterns of prediction suggest that the ‘pure’ forms of migraine and MDD are
genetically distinct disorders. The subgroup of individuals with comorbid MDD and migraine
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were genetically most similar to MDD patients. These results indicate that in at least a subset of
migraine patients with MDD, migraine may be a symptom or consequence of MDD.
Keywords
depression; migraine; polygenic score; genetic risk score; causality; genetics; comorbidity
Introduction
There is a well-established comorbidity between migraine and major depressive disorder
(MDD), with a 2–3 times higher risk of migraine in MDD patients than in non-MDD
controls (Ligthart et al. 2010b). Both conditions are around 40–50% heritable (Levinson
2006; Mulder et al. 2003), and thought to be influenced by a large number of genetic
variants with small effects. Longitudinal studies show mixed results with respect to the order
of onset of migraine and depression (Antonaci et al. 2011; Swartz et al. 2000). There is some
evidence suggesting that anxiety disorders tend to precede migraine, whereas depression
tends to follow migraine (Breslau et al. 1991; Merikangas et al. 1990), but a bidirectional
relationship has also been reported, with migraine predicting depression onset and vice versa
(Breslau et al. 2000; Breslau et al. 2003). We previously showed, in a bivariate twin study,
that migraine and depression are partly influenced by the same genes, with a correlation of
around 0.3 between the genetic factors affecting the two disorders (Ligthart et al. 2010a).
Several other studies reported similar results (Schur et al. 2009; Stam et al. 2010).
While genetic correlations are often interpreted as the same genes directly affecting multiple
conditions, alternative explanations are possible, including cross-assortative mating (Hazel
1943) or the causal effect of one trait on the other (De Moor et al. 2008). In our twin study,
we found that in monozygotic twin pairs discordant for anxious depression, the twins with a
high anxious depression score had an increased risk of migraine; their non-anxious-
depressed co-twins did not, even though they had the same genetic make-up as the anxious-
depressed twin. Similarly, in pairs discordant for migraine, only twins with migraine had an
increased risk of anxious depression (Ligthart et al. 2010a). This suggests that a causal
relationship (one trait causing the other), rather than genes directly involved in multiple
disorders (pleiotropy), may explain the comorbidity of migraine and depression (De Moor et
al. 2008; Ligthart and Boomsma 2012).
A possible causal explanation is that a severe pain disorder such as migraine might reduce a
patient’s quality of life, resulting in depressive symptoms. However, a study on back pain
and depression found no relationship between pain duration and depression severity, which
would be expected if it is the long-lasting pain and disability that causes the depressive
symptoms (Von Korff and Simon 1996). Alternatively, migraine might be a symptom or
consequence of depression. Pain symptoms are remarkably common in depressed patients,
and some have argued that pain should be viewed as an integral part of the depression
phenotype (Lépine and Briley 2004; Stahl 2002). Currently, solid evidence for this
hypothesis is lacking.
Here, we investigate the comorbidity of migraine and depression at the measured genotype
level, by using genetic risk scores (based on SNP risk alleles) obtained in one (discovery)
sample to predict migraine and depression status in another, independent (target) sample.
With this method, the combined effects of a large number of SNPs on a trait or disorder,
estimated in a discovery sample, are used to construct a ‘genetic risk score’ for individuals
in an independent target sample. The genetic risk score is a single quantitative index of
genetic load for the discovery trait, and can be used to ‘predict’ phenotype status in
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individuals in the target sample (Purcell et al. 2009). This method allows the comparison of
specific groups of patients in terms of their genetic similarity, and has previously been
applied to demonstrate overlap in genetic influences across disorders, such as schizophrenia
and bipolar disorder (Purcell et al. 2009), and anxiety and depression (Demirkan et al.
2010).
Here, we apply this method to investigate possible causal relationships between two
phenotypes. Our first hypothesis is that some migraines are a consequence of depression (or
are a symptom of depression; since these two hypotheses are closely related and yield the
same predictions we will not distinguish between them). According to this hypothesis,
migraine due to depression will be genetically similar to depression, but not to migraine
without depression (further referred to as pure migraine). This is based on the principle that
if disease A causes disease B, the genes that affect disease A must indirectly also affect
disease B, through the causal chain (De Moor et al. 2008; Ligthart and Boomsma 2012).
Two alternative hypotheses were considered. Hypothesis 2 was the reverse of hypothesis 1:
depression can be a consequence (or symptom) of migraine, and depression due to migraine
is genetically similar to migraine, but not to depression without migraine (further referred to
as pure depression). Hypothesis 3 was that there is only one type of migraine and one type
of depression, which are in part influenced by genes involved in both disorders. However,
the latter is not expected given our previous findings (Ligthart et al. 2010a).
Materials and methods
Discovery sample migraine: the Australian Twin Migraine (ATM) GWA Study
The ATM study includes data from Australian twins and their families. Detailed migraine
data were collected by means of semi-structured telephone interviews, with a mean age at
interview of 37.5 years [SD = 11.3] (Nyholt et al. 2004; Nyholt et al. 2005). The
questionnaire was based on the symptoms from the ICHD-II diagnostic criteria (2004). All
subjects gave informed consent and approval to conduct the research was obtained from the
QIMR Human Research Ethics Committee. Participants were classified as affected or
unaffected with latent class analysis (LCA), as described in detail in previous work (Nyholt
et al. 2004; Nyholt et al. 2005). All GWA cases screened positive for migraine according to
ICHD-II migraine with aura (MA) and/or migraine without aura (MO) diagnostic criteria, or
the ID Migraine™ Screener (Lipton et al. 2003), which has been shown to accurately
identify 93% of people with migraines. Additional migraine cases were identified from other
questionnaire data as those self-reporting (“yes” or “no”) to suffering migraine. All cases
and controls were unrelated; one individual was selected from each family. The cases (N =
2,825; 752 [27%] male, 2,073 [73%] female) were preferentially selected from each family
based on migraine severity. The population controls (N = 3,525; 1,814 [51%] male, 1,711
[49%] female) were randomly selected from families containing no known migraine cases.
There were 805 individuals known to have MDD, based on DSM-IV criteria (Wray et al.
2010); after exclusion of these MDD cases there were 2155 cases and 3390 controls (for
details see Table 1).
The subjects were drawn from the QIMR GWA cohort of over 19,000 individuals genotyped
using a variety of Illumina GWA arrays. After strict QC, allelic association analysis was
performed using the PLINK program. For a detailed description of the QIMR 19K GWA
cohort, including QC, see Medland et al. (2009).
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Discovery sample MDD: the RADIANT study
The UK RADIANT study consisted of 1636 depression cases and 1594 non-MDD controls
from the UK (Table 1). The participants came from two studies on recurrent depression (the
Depression Case Control [DeCC] study and the Depression Network [DeNT] study) and a
pharmacogenetic study (the Genome-Based Therapeutic Drugs from Depression [GENDEP]
study), which have been described in more detail previously (Cohen-Woods et al. 2009;
Farmer et al. 2004; Uher et al. 2009). The mean age of onset was 23.1 years (SD = 11.4) and
66.4% of cases were female.
MDD was diagnosed with the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN) interview. A case was defined as a patient with recurrent depression (DeCC and
DeNT) or experiencing a current episode of depression (GENDEP) of at least moderate
severity, according to either DSM-IV or ICD-10 criteria. The controls were volunteers
recruited via the Medical Research Council general practice research framework and staff
and students of King’s College London, who were screened for lifetime depressive
symptoms with a telephone interview.
Genotyping was performed using the Illumina Human Hap610-Quad BeadChips. Exclusion
criteria were a missing genotype rate > 1%, abnormal heterozygosity, inconsistencies with
respect to sex assignment, relatedness with other participants or non-Caucasian ancestry.
SNPs were excluded based on MAF < 1%, or significant departure from HWE (P < 1×10−5).
Genome-wide association analysis was performed with logistic regression analysis,
assuming a log-additive model and including ancestry principal components as covariates.
Details can be found elsewhere (Lewis et al. 2010).
Target sample: the NTR-NESDA study
The target sample included participants from the Netherlands Twin Registry [NTR]
(Boomsma et al. 2006) and the Netherlands Study of Depression and Anxiety [NESDA]
(Penninx et al. 2008). Genotyping was performed in the context of the GAIN study on MDD
(Boomsma et al. 2008; Sullivan et al. 2008). The NTR data were part of an ongoing
longitudinal study on health, personality and lifestyle in Dutch twin families (Boomsma et
al. 2006). NESDA is a longitudinal study on anxiety and depression, with participants from
the general population, primary care, and specialized mental health care (Penninx et al.
2008). The mean age of the participants was 42.3 years (SD = 16.5; 65% female).
Cases with lifetime MDD (N=1480) were diagnosed based on DSM-IV criteria with the
Composite International Diagnostic Interview (Wittchen 1994). The control group (N=1491)
consisted of individuals selected for low risk of MDD based on measures of depression,
anxiety and neuroticism (Boomsma et al. 2008). Migraine was measured with questionnaire
items based on the symptoms included in the ICHD-II criteria for migraine (2004). As in the
ATM study, affection status was determined by means of LCA, as described in previous
work (Ligthart et al. 2006). Table 1 provides an overview of the numbers of patients with
“pure” and comorbid forms of migraine and MDD.
The analyses in this paper are based on 2966 unrelated individuals from the GAIN-MDD
study (Boomsma et al. 2008; Sullivan et al. 2008) with data on both migraine and MDD,
who were genotyped on the Affymetrix Perlegen 5.0 platform. Genotype imputation was
performed on a larger dataset, including samples genotyped on several different platforms.
Inclusion criteria for SNPs were MAF > 1%, HWE P > 0.00001 and call rate > 95%.
Individuals were excluded when their expected sex and IBD status did not match, when the
mean heterozygosity was < 0.30 or > 0.35, or when the missing genotype rate exceeded
10%. All SNPs were aligned to the positive strand of the Hapmap 2 Build 36 release 24
CEU reference set. The alignment was checked using individuals and family members tested
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on multiple platforms. SNPs were excluded per platform if allele frequencies differed more
than 15% with the reference set and/or the other platforms. The data were subsequently
merged into a single dataset (N = 5856), and imputed against the reference set using
IMPUTE v2 (Marchini and Howie 2010). After imputation, genotype dosage was calculated
if the highest genotype probability was above 90%. Badly imputed SNPs were removed
based on HWE P < 0.00001, proper info < 0.40, MAF < 1%, allele frequency difference >
0.15 against reference.
Genetic risk score analyses
To explore whether common variants with small effects on MDD and migraine status
together predicted affection status in an independent sample, a genetic risk score test was
performed following the method introduced in Purcell et al. (2009), and implemented in the
PLINK program (Purcell et al. 2007). Twelve different SNP sets were selected for the
prediction analyses (with P-value thresholds at .01, .05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9, 1.0). Only SNPs directly genotyped in the discovery samples were included. The
number of SNPs overlapping between discovery and target samples was 249,917 for ATM
and NTR-NESDA, 416,030 for RADIANT and NTR-NESDA, and 229,778 SNPs were
available in all three samples. The numbers of SNPs included in each of the analyses are
listed in Table 2. For each individual in the target sample, genetic risk scores were
calculated based on the estimated number of ‘risk alleles’ an individual possessed
(accounting for uncertainty of imputation in the target sample), weighted by the log odds
ratio (i.e., effect size) for that allele calculated in the discovery sample. With this procedure,
three genetic risk scores were calculated for each individual, one based on RADIANT
MDD, one based on ATM migraine and one based on ATM migraine with MDD cases
excluded.
Next, it was tested whether higher mean genetic risk scores were observed for cases than for
controls in the target sample. Several different definitions of case status were used: all
migraine, all MDD, pure migraine, pure MDD, and comorbid MDD+migraine. The cases
were compared with controls unaffected for both migraine and MDD. The association
between mean genetic risk score and case/control status in the target sample was tested
using logistic regression analysis in R v2.11.0. Nagelkerke’s pseudo R2 was used to assess
the variance explained. In addition, to assess predictive ability, the area under the receiver
operating characteristic (ROC) curve (AUC) was calculated using the PredictABEL R
package (Kundu et al., 2011). Given the unequal sex ratio of migraine and MDD, prediction
analyses were compared including or excluding sex as a covariate.
Under all hypotheses, we expect prediction of a phenotype from genetic risk scores based on
the same phenotype in another sample to be significant. Prediction of migraine from
depression scores or vice versa will be somewhat weaker but still significant. The
hypotheses yield different expected predictions when the “pure” forms of either migraine or
depression are predicted from the other phenotype (see Table 3).
When pure migraine is predicted from depression genetic risk scores, we expect no
prediction under hypothesis 1 (because pure migraine is genetically distinct from MDD).
Whereas we expect to see modest but significant prediction under hypothesis 2 (because
some cases of MDD are a symptom or consequence of migraine, and therefore, migraine
risk variants will be part of the MDD risk profile). Modest but significant prediction is also
expected under hypothesis 3 (because migraine and MDD are partly affected by the same
genetic risk factors, and therefore migraine patients will possess some risk variants for
MDD, regardless of MDD status).
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When pure depression is predicted from migraine genetic risk scores, expectations under
hypothesis 1 will depend on whether MDD is predicted from all migraine or pure migraine.
Pure depression prediction from all migraine is expected to be modest but significant
(because all migraine is a combination of pure migraine and migraine due to MDD).
Whereas pure depression predicted from pure migraine is not expected (because pure
migraine and pure MDD are genetically distinct disorders). Under hypothesis 2, we expect
to see no significant prediction (because pure MDD cases do not have migraine and
therefore do not share migraine risk factors), and under hypothesis 3, the prediction is
expected to be modest but significant (because migraine and MDD are partly affected by the
same genetic risk factors).
Because there were different numbers of cases for the different phenotypes, the sample sizes
differed considerably between analyses. To assess how these differences in sample size
might affect our results, the smallest sample size in the target sample was taken (335 cases
for pure migraine vs. 1155 controls, see Table 1) and the prediction analyses for the other
phenotypes were repeated 10,000 times with random samples of 335 cases drawn from the
total sample available for each phenotype. Mean R2 and P-values across the 10,000
permutations were calculated in order to assess the effect of sample size on the significance
and explained variance, compared with the original analyses. The number of SNPs also
differed between the RADIANT and ATM samples. Therefore, the analyses were repeated
using only the SNPs available in all three samples, to test to what extent the results were
affected by the number of SNPs included.
SNP effect (direction) concordance analysis
To further investigate the polygenic overlap of migraine (before and after excluding MDD
individuals) with pure MDD, we examined the correlation of individual SNP effects across
the datasets. That is, we tested whether the direction of SNP effects were positively
correlated across the i) all migraine (ATM) vs. pure MDD (NTR-NESDA), and ii) pure
migraine (ATM excluding MDD cases) vs. pure MDD (NTR-NESDA) GWA results.
Firstly, the SNP effects [i.e., odds ratio (OR)] were aligned to the same reference allele at
each SNP across the two GWA results (ATM and NTR-NESDA). After alignment, a subset
of independent SNPs was extracted via linkage disequilibrium (LD) clumping (Purcell et al.
2007), i.e., removal of SNPs in LD with r2 > 0.1 estimated using HapMap 3 (release 2) CEU
SNP genotype data. To test whether the effect directions were concordant across the
datasets, we performed Fisher’s Exact statistical tests of SNP effects in dataset1 (OR1) and
dataset2 (OR2) after conditioning on their GWA p-values. Briefly, for each subset, Fisher’s
Exact tests were performed on 2×2 tables containing the number of SNPs with both OR1<1
and OR2<1 (OR1<1 ∩OR2<1), OR1>1 ∩OR2<1, OR1<1 ∩OR2>1, and OR1>1 ∩OR2>1.
SNP subsets were generated utilising the same twelve p-value thresholds used in the genetic
risk score analyses in ATM and NTR-NESDA. To examine the overall concordance in SNP
effects between two datasets, we calculated the proportion of the total (144) threshold
combination subsets where the SNP effects were nominally correlated [Fisher’s Exact test p-
value (PFT) ≤0.05]. To examine the significance of observing a specific proportion of
subsets with correlated SNP effects, we performed 10,000 permutations where for each
replicate the SNP effect and p-value were randomly shuffled in the ATM migraine GWA
results before generating SNP subsets and performing Fisher’s Exact tests. Note that only
the SNP name-effect relationship in the ATM migraine GWA results is destroyed by
permutation to provide a new dataset sampled under the null hypothesis: the effect direction
and p-value pattern will remain the same under the observed and permuted subsets.
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Results
The results of the genetic risk score analyses are summarized in Fig. 1. Although sex was
significant in the relationship between genetic risk score and phenotype (due to the unequal
sex ratio of migraine and MDD), including sex did not change the conclusions regarding the
significance of the genetic risk score. Therefore, results are only provided for analyses
excluding sex as a covariate.
Genetic risk scores based on the RADIANT MDD results (Fig. 1a) were significantly
predictive of all MDD status in NTR-NESDA (maximum Nagelkerke’s pseudo-R2 = 0.0080,
P = 7.5×10−5, AUC = 0.545 at PT = 0.5). RADIANT MDD-scores also predicted pure MDD
(R2 = 0.0069, P = 0.0019, AUC = 0.543 at PT = 0.3). The proportion of explained variance
was highest for the comorbid MDD+migraine phenotype (R2 = 0.0091, P = 4×10−4, AUC =
0.546 at PT = 0.6). Furthermore, RADIANT-MDD was significantly predictive of all
migraine in NTR-NESDA (R2 = 0.0061, P = 0.0015, AUC = 0.537 at PT = 0.3). However,
consistent with hypothesis 1, and inconsistent with hypotheses 2 and 3, the RADIANT-
MDD genetic risk score did not significantly predict pure migraine (R2 = 0.0037, P = 0.058,
AUC = 0.530 at PT < 0.05 and considerably weaker at all other cut-offs).
Similarly, genetic risk scores for migraine based on the ATM data (Fig. 1b) significantly
predicted all migraine (R2 = 0.0058, P = 0.002, AUC = 0.533 at PT = 0.6), pure migraine
(R2 = 0.0053, P = 0.023, AUC = 0.532 at PT = 0.3) and comorbid MDD+migraine (R2 =
0.0054, P = 0.007, AUC = 0.535 at PT = 0.2) in NTR- NESDA. ATM migraine also
predicted all MDD, albeit more weakly (R2 = 0.0040, P = 0.0052, AUC = 0.527 at PT = 0.3).
ATM migraine was very modestly predictive of pure MDD, marginally significant only at
PT < 0.3 (R2 = 0.0028, P = 0.046, AUC = 0.520). According to hypothesis 1, this prediction
should disappear once MDD cases are removed from the analysis in the discovery sample,
and this was indeed observed. After 805 MDD cases were excluded from the ATM sample
(Fig. 1c), the genetic risk scores for migraine no longer predicted pure MDD (R2 = 0.0016, P
= 0.14, AUC = 0.518, PT = 0.05). To test whether this lack of prediction was due to the
reduced discovery GWA sample size, we compared these results with those of 1000
analyses in which 805 individuals were dropped at random (Fig. 2). The results indicated
that although the reduced sample size had a small effect on the amount of explained
variance, there was a clear relationship with the MDD status of the individuals removed. In
the original analyses (Fig. 1b vs. 1c), the reduction in explained variance was strongly
related to the presence of MDD in the case group: the drop in prediction was considerable
for all phenotypes except pure migraine. In the analyses where randomly selected
individuals were excluded (Fig. 2), the predictive strength dropped by roughly the same
amount for all phenotypes. That is, the drop in prediction of pure MDD in NTR-NESDA
using ATM migraine genetic risk scores after excluding MDD individuals was greater than
expected by chance.
Next, we tested to what extent our results might be biased by differences in sample size
between the different subsets. To investigate this, the prediction analyses were repeated
10,000 times with random samples of 335 cases and 1155 controls (equal to the size of the
smallest target sample, pure migraine), drawn from the total sample available for each of the
other phenotypes. The results showed that, while the significance was affected by sample
size (reflected by larger P-values), the reduced sample size had only a very modest effect on
the amount of explained variance (Fig. 3). Importantly, the observed patterns in predictive
strength remained highly similar. Hence the observed differences in R2 between phenotypes
were not due to differences in sample size.
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Furthermore, to investigate the impact of the larger number of SNPs in the RADIANT than
in the ATM sample, the prediction analyses were repeated using only the SNPs that
overlapped between all three samples (N = 229,778). This produced only a minor decrease
in the explained variance (Fig. 4), and very similar prediction patterns.
Finally, examination of individual SNP effects across the datasets supported the results of
our genetic risk scores analyses. For the all migraine and pure MDD GWA results, SNP
effects were nominally correlated [Fisher’s Exact Test p-value (PFT) ≤0.05] in 21 of the total
144 threshold combination subsets. Importantly, for all 21 subsets the SNP effects were in
the same direction producing a Fisher’s Exact Test Odds Ratio (ORFT) >1. Out of 10,000
permuted replicates, only 360 produced 21 or more subsets with ORFT >1 and PFT ≤0.05
(PFT-permuted = 0.036; 95%CI: 0.033–0.040). In contrast, for the pure migraine and pure
MDD GWA results, SNP effects were nominally correlated (PFT ≤0.05) in only 2 of the total
144 threshold combination subsets. Importantly, the SNP effects were in the opposite
direction in these two subsets (ORFT < 1). Out of 10,000 replicates, 5,510 produced zero
subsets with ORFT >1 and PFT ≤0.05 (PFT-permuted = 0.551; 95%CI: 0.541–0.561)— in line
with that expected under the null hypothesis of the SNP effects being uncorrelated between
datasets.
The substantial and significant reduction in correlation of SNP effects between pure
migraine and pure MDD compared to all migraine and pure MDD provides clear support for
the observed polygenic overlap between migraine and depression being due to individuals
comorbid for both traits and that the ‘pure’ forms of migraine and MDD are genetically
distinct disorders.
Discussion
Several novel and important findings emerge from this study. First, the results confirm the
assumed polygenic nature of both MDD and common migraine and indicate that many SNPs
conferring true, albeit weak risk, remain to be identified. Second, this is the first study
showing the overlap in genetic influences on migraine and MDD, previously found in twin
and family studies, at the measured genotype level. Third, and most importantly, we
developed a new application of genetic risk scores to investigate causality, and our results
support the hypothesis that in a subset of patients, migraine is a symptom or consequence of
MDD. Although MDD genetic risk scores predict migraine and vice versa, pure migraine
appears to be genetically distinct from MDD. This means that the observed overlap in the
genetic factors influencing migraine and MDD is most likely explained by the subgroup of
individuals with comorbid MDD+migraine. If migraine is indeed the result and not the
cause of depression, these comorbid cases should be genetically very similar to MDD
patients. Fig. 1 shows that this is indeed the case: comorbid MDD+migraine was in fact the
phenotype most strongly predicted by genetic risk scores for MDD (Fig. 1a), possibly
reflecting that these patients have a more severe form of depression, and are therefore more
likely to experience migraine headaches, as would be expected if migraine were a symptom
or consequence of MDD. On the other hand, comorbid MDD+migraine was also (more
weakly) predicted by all migraine (Fig. 1b), and some marginally significant prediction
remained even after exclusion of MDD cases from the migraine discovery sample (Fig. 1c).
This could be explained by the presence of individuals with undiagnosed MDD within the
ATM sample, or the high prevalence of migraine and MDD, where some individuals are
expected to possess risk variants for both migraine and MDD by chance. Therefore, the
comorbid group will be a mixture of ‘true’, ‘genetically comorbid’ cases, and cases who
have both migraine and MDD by chance.
Ligthart et al. Page 8
Hum Genet. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Consistency with previous findings
The finding that migraine may be a symptom or consequence of depression is consistent
with our previous findings based on discordant twin analysis, which suggested that the mere
existence of genes affecting multiple disorders is insufficient to explain the relationship
between migraine and depression, and that a causal or syndromic relationship would be a
plausible explanation for the observed comorbidity. Although it might be expected that this
type of relationship is associated with a specific order of onset (first depression, then
migraine), this is not necessarily the case. If migraine is the ’byproduct’ of an underlying
depression, the migraine may have its onset either before or after the patient is officially
diagnosed with MDD (assuming the first symptoms of depression occur sometime before all
diagnostic criteria for MDD are fulfilled). This is entirely consistent with the mixed findings
of previous longitudinal studies (Antonaci et al. 2011; Breslau et al. 1991; Breslau et al.
2000; Breslau et al. 2003; Merikangas et al. 1990; Swartz et al. 2000). Detailed longitudinal
studies at the level of symptoms are required to achieve more insight into the developmental
trajectories associated with the combination of depressive symptoms and migraine
headaches.
Strengths and limitations
A major strength of this study is that the target sample was phenotypically well
characterized for both migraine and MDD. Subjects were selected based on MDD status,
such that cases met strict clinical diagnostic criteria for MDD and controls were at low risk
for MDD. This allowed a strict distinction between migraineurs with and without MDD. In
addition, very similar phenotyping procedures were used across target and discovery
samples, which ensure that predictions were not limited by differences in phenotype
definitions.
A limitation is that the genetic risk scores explained only a small proportion of variance,
limiting the predictive ability of the method. This is consistent with findings in previous
studies using similar designs and phenotypes (e.g., Demirkan et al. 2010; Middeldorp et al.
2011; Purcell et al. 2009), and expected given the small effects of individual genetic variants
on complex traits (Dudbridge 2013). When individual genetic variants have small effects,
the effect size estimates will be associated with large standard errors, which limit the
strength of the correlation between predicted and observed phenotypes, and therefore the
proportion of explained variance (Davies et al. 2011). Moreover, our genetic risk score was
not restricted to robustly implicated risk loci; hence the majority of SNP effects in the
discovery samples will not be true risk effects. However, the main aim of this study was to
analyze patterns in predictive strength and association testing of genetic risk scores, which is
possible even when the proportion of explained variance is low, assuming that the variance
captured by the measured SNPs is representative of the remaining variance.
Using RADIANT MDD scores to predict migraine and MDD produced more accurate
predictions (i.e., explained more variance) than using ATM migraine scores, even though
the ATM sample was larger. This might be related to the larger number of SNPs that
overlapped between NTR-NESDA and RADIANT. However, restricting the analyses to the
SNP set that overlapped between all three samples (N = 229,778) produced only a minor
decrease in the explained variance (Fig. 4). A more important factor may be that for MDD a
more stringent phenotype definition was used than for migraine. The migraine cases were
not ascertained based on phenotype status, but drawn from a population-based sample,
which includes many genetically informative subclinical migraineurs. A stricter phenotype
definition excludes many of these individuals, which effectively results in a loss of statistical
power. However, similar patterns were observed under stricter definitions of migraine, for
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instance, ICHD-II MO/MA cases [data not shown] (Headache Classification Committee of
the International Headache Society, 2004).
Finally, although migraine was assessed in a large part of the RADIANT sample (Samaan et
al., 2010), for a subset of participants this information was not available. Therefore, we did
not perform an analysis in which migraine cases were excluded. However, as expected, in
participants with migraine data migraine status was significantly associated with MDD: the
prevalence of migraine was 29% in the MDD cases and 11% in non-MDD controls (OR =
2.6, 95% CI 2.0–3.4). In spite of the considerable number of migraineurs and the strong
association between migraine and MDD in the RADIANT sample, the MDD genetic risk
scores did not predict pure migraine, supporting the hypothesis that migraine associated with
MDD is genetically different from pure migraine. It is expected that this would not change if
all migraineurs were excluded from the sample.
Implications
The results of this study imply that some cases of migraine are a result of MDD, and
that ’pure’ and MDD-related migraine are etiologically different disorders. This has
important implications for research and treatment. Firstly, in genetic studies, a distinction
should be made between pure migraine and migraine accompanied by depression. The same
may apply to other, both psychiatric and non-psychiatric disorders that are comorbid with
migraine. Perhaps common migraine might be better viewed as a group of disorders with
similar symptomatology but (genetically) different etiologies, rather than as a single
disorder.
Secondly, patients with MDD-related migraine might require a different course of treatment,
or respond differently to certain types of treatment (e.g. with antidepressants) than patients
with migraine unrelated to MDD. An important and unanswered question is whether
successful treatment of MDD leads to a reduction in migraine symptoms. Well-designed
studies targeted specifically at this research question are needed to address this.
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Fig. 1.
Prediction of migraine/MDD phenotypes from scores based on RADIANT MDD (A), ATM
migraine (B) and ATM migraine after exclusion of 805 MDD cases (C). Results are shown
for P-value thresholds between .01 and .6 (indicated below the bars). The P-values above the
bars indicate the significance of each test
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Fig. 2.
Averaged results of predictions based on 1000 permutations in the ATM data, in each of
which a random sample of 805 individuals was removed from the dataset. Compared to the
original analysis based on all ATM participants (Fig. 1b), this figure shows a small and
consistent reduction in R2 which is independent of the phenotype. However, in the analysis
excluding the 805 MDD cases (Fig. 1c), the reduction is very limited for pure migraine, but
larger for the other phenotypes (which all include some cases with MDD). This indicates
that the different results in ATM before and after removal of the MDD cases are indeed
explained by MDD and not merely by differences in sample size
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Fig. 3.
Averaged results based on 10.000 permutations in which random samples were drawn with
sample size equal to the smallest dataset (pure migraine, N = 335 cases and 1155 controls).
Results are shown for predictions based on RADIANT (Fig. 3a), ATM (Fig 3b), and ATM
after exclusion of 805 MDD cases (Fig. 3c). Note that for pure migraine, the original results
are shown since no permutations were run for the smallest dataset
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Fig. 4.
Results of analyses restricted to SNPs overlapping between all three samples (N = 229,778),
for predictions based on RADIANT (Fig. 4a), ATM (Fig. 4b) and ATM after exclusion of
805 MDD cases (Fig. 4c)
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Table 1
Sample sizes and number of cases with migraine and/or MDD
Australian Twin Migraine (ATM) study (discovery) Total sample MDD cases Excluding MDD
Total sample 6350 805 5545
Migraine cases 2825 670 2155
Controls 3525 135 3390
RADIANT MDD study (discovery) Total sample
Total sample 3230 - -
MDD cases 1636 - -
Controls 1594 - -
NTR-NESDA study (target) Total sample NTR NESDA
Total sample 2966 1442 1524
Controls 1155 1050 105
Pure migraine 335 296 39
Pure MDD 753 48 705
Comorbid MDD+migraine 723 48 675
Total MDD cases 1476 96 1380
Total migraine cases 1058 344 714
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Table 3
Expected patterns of prediction under the three hypotheses
Significant prediction expected (yes/no)
Genetic risk scores based on: Predicted phenotype (NTR-NESDA) Hypothesis 1:
migraine due to
MDD
Hypothesis 2:
MDD due to
migraine
Hypothesis 3:
shared genes
All MDD (RADIANT) Pure migraine No Yes Yes
All migraine (ATM) Pure MDD Yes No Yes
Pure migraine (ATM, excl.
MDD cases)
Pure MDD No No Yes
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